Glax­o­SmithK­line scraps a LAG3 study, mark­ing an­oth­er fail­ure for the pipeline af­ter a crit­i­cal set­back

An­oth­er gap has ap­peared in Glax­o­SmithK­line’s pipeline.

Fri­day morn­ing the Aus­tralian biotech Im­mutep put out word that Hal Bar­ron’s R&D group at GSK had de­cid­ed to scrap a Phase II proof-of-con­cept study in ul­cer­a­tive col­i­tis for their an­ti-LAG3 ther­a­py GSK2831781. Ac­cord­ing to the biotech, the pro­gram didn’t sur­vive an in­ter­im re­view.

The tri­al was stopped by GSK based on the as­sess­ment of clin­i­cal da­ta as part of a planned in­ter­im analy­sis con­duct­ed in con­sul­ta­tion with the tri­al’s Da­ta Re­view Com­mit­tee. GSK is con­duct­ing fur­ther re­port­ing, as­sess­ment and analy­ses of the ef­fi­ca­cy and safe­ty da­ta and eval­u­at­ing the bi­ol­o­gy to de­ter­mine next steps for the GSK2831781 de­vel­op­ment pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.